Fevertree Drinks

Fevertree reports currency‑adjusted brand revenue growth of 8% in the first half of 2026 and increased US growth of 11%, while products beyond tonic water now make up almost half of revenue. Adjusted EBITDA margin improved by 20 basis points to 10.9% and normalized EPS rose 5%. Management expects US growth to accelerate in H2, plans local US production and forecasts free cash flow of at least £100m for 2027/28; nonetheless the stock fell 5.13% in pre-market trading. » More on de.investing.com

Laura Hagan will step down from her mandate as a non-executive director at Fevertree Drinks at the end of July. She had served on the board since May 2021, was chair of the remuneration committee and a member of the audit and nomination committees. After her departure, David Lapp will assume the chair of the remuneration committee. » More on de.investing.com

Fevertree shares rose about 6.3% to 806.5 pence after the annual general meeting, driven by a trading update and the expansion of the buyback program. Management confirmed the brand is gaining market share in core regions and reiterated its full-year guidance. Analysts remain divided: some see significant upside potential, while others warn of high valuation multiples and declining revenue trends. » More on de.investing.com